<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Toll-like receptor 9 (TLR9) triggering is a promising novel strategy to combat <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> as it induces innate and adaptive immunity responses </plain></SENT>
<SENT sid="1" pm="."><plain>B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is unique in this context as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells express TLR9 and may harbor latent Epstein-Barr virus (EBV), a gamma-herpesvirus with remarkable oncogenic potential when latent </plain></SENT>
<SENT sid="2" pm="."><plain>Latent EBV may be promoted by TLR9 triggering via suppression of lytic EBV </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we elaborated an initial assessment of the impact of TLR9 triggering on EBV-positive and EBV-negative B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> using Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cell lines as an in vitro model </plain></SENT>
<SENT sid="4" pm="."><plain>We show that, independent of the presence of EBV, the TLR9 ligand oligodeoxynucleotide (ODN) CpG-2006 may or may not induce caspase-dependent cell <z:hpo ids='HP_0011420'>death</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, ODN CpG-2006-induced cell <z:hpo ids='HP_0011420'>death</z:hpo> responses of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells were associated with TLR9 single-nucleotide polymorphisms (SNPs) rs5743836 or rs352140, which we detected in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and in peripheral blood from healthy individuals at similar frequencies </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, our findings suggest that the effect of TLR9 <z:chebi fb="4" ids="48705">agonists</z:chebi> on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells should be tested in vitro before installment of therapy and TLR9 SNPs in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> patients should be determined as potential biological markers for the therapeutic response to treatment targeting innate immunity </plain></SENT>
</text></document>